The global demand for Amyloid Peptides Market is presumed to reach the valuation of nearly USD XX MN by 2026 from USD XX MN in 2019 with a CAGR of XX% under the study period of 2020 - 2026.
An amyloid peptide is a 42-amino acid peptide that plays a central role in Alzheimer's disease pathology in humans. It is the primary therapeutic target to arrest the course of this disease. Several amyloid peptide-based compounds are used for the early diagnosis and treatment of AD and peptide-based inhibitors for targeting various aggregation checkpoints. The amyloid peptide is involved in protecting and repairing the central nervous system and is associated with over 30 diseases like Huntington's, Parkinson's, amyotrophic lateral sclerosis, and type II diabetes. It also functions as a group of biomolecules known as "antimicrobial peptides" and can inhibit eight of 12 crucial clinical pathogens' growth.
Increasing incidences of Alzheimer's among the global geriatric population and extensive research carried out globally to develop peptide-based compounds for the initial diagnosis and treatment of the disease are the central stimulants for this market's growth. Amyloid peptide-based drugs have emerged as a significant therapeutics class for treating fatal conditions like AD and cancer since they can efficiently inhibit pathological peptides' production and aggregation. The expanding healthcare sector and growing investments in innovative drugs to treat neurological disorders will benefit market growth. The main concerns regarding the use of amyloid peptides are the formation of excess amyloid oligomers and amyloid plaques due to an imbalance in production and clearing of the peptide leading to neurotoxicity.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of amyloid peptides.
The entire amyloid peptides market has been sub-categorized into type and applications. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
- Beta-Amyloid Mouse
- Beta-Amyloid Rat
- Beta-Amyloid Human
- Alzheimer’s Disease Research
- Cancer Research
- Lewy Body Dementia Research
- Inclusion Body Myositis Research
- Cerebral Amyloid Angiopathy Research
This section covers regional segmentation which accentuates on current and future demand for amyloid peptides market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Amyloid Peptides Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the amyloid peptides market include AmideBio, Cambridge Research Biochemicals, BioLegend, AnaSpec, Inc., rPeptide, Genscript, Bio-Synthesis, NovoPro Inc., Bachem. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.